MARKERS FOR DAT: CONTROL, VARIABILITY AND PERSONALITY
DAT 的标记:控制、可变性和个性
基本信息
- 批准号:7578740
- 负责人:
- 金额:$ 16.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-15 至 2013-12-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAreaAttentionBehavioralBehavioral AssayBiological MarkersCharacteristicsCognitiveDataDiseaseDissociationElderlyExclusionFamiliarityFutureGeneticGoalsHourIndividualIndividual DifferencesLeadMeasuresMedialMedicineMemoryNeurotic DisordersOnset of illnessParticipantPerformancePersonalityPersonality TraitsPredispositionPrincipal InvestigatorProceduresProcessReaction TimeResearchResponse LatenciesRetrievalRiskRoleSemanticsSenile dementiaStagingStrokeSystemTechniquesTestingTraining Technicsbasecognitive changeexecutive functionhealthy agingnovelprogramsprospectiveprospective memory
项目摘要
There is accumulating evidence that early stage Alzheimer's disease reflects a breakdown in attentional
control systems that likely contribute to the changes in memory performance, along with other aspects of
cognitive performance. Recent evidence indicates that tasks that place a maximum load on attentional
systems are particularly useful in serving as a behavioral biomarker both in discriminating healthy aging from
early stage DAT, and are correlated with other biomarkers in non-demented older adults. The proposed
research plan will continue to longitudinally follow a set of healthy older adults and individuals in the early
stages of the disease process, along with individuals who are at risk due to stroke, to better isolate the
contributions of novel attentional control measures, and to investigate the extent to which these individuals
respond to memory/attention training techniques. We will have three waves of testing, which will be
separated by approximately 1.5 years. Each participant will be tested in a single session for each wave of
testing, lasting approximately 2 hours. During each wave, we will continue to administer a small battery (no
more than 40 minutes) of executive measures (computation span, Stroop, a retroactive interference
exclusion measure, and a short switching task). This will afford the ability to continue to follow these
individuals with the same set of measures for which we already have data. In addition to the executive
control measures, we will also use experimental procedures to provide estimates of three different targeted
components in each wave. These will include measures of (a) controlled and automatic processing via the
processing dissociation procedure, (b) components of prospective memory performance, and (c) standard
mnemonic manipulations (i.e., repeated testing, expanded retrieval, semantic encoding).
We will continue to explore distinct measures of participant variability and the components of reaction
time distributions that lead to any change in the observed variability estimates as a potential marker for
cognitive changes in healthy aging and early stage DAT. In addition, because of recent evidence that certain
personality traits (e.g., conscientiousness and neuroticism) predispose individuals for developing DAT, we
will explore the modulatory role of personality characteristics in the cognitive markers, and susceptibility to
mnemonic techniques. Moreover, we have recently found that personality characteristics are related to
cognitive performance including variability estimates. Finally, the behavioral assays obtained in Project 3 will
be correlated with the results from the biomarkers available from other projects and cores (e.g., CSF, PIB,
genetics, and volumetric measures of targeted areas) to determine which composite measures afford the
best behavioral biomarkers.
越来越多的证据表明,早期阿尔茨海默病反映了注意力的崩溃
控制系统,可能有助于存储器性能的变化,沿着的其他方面,
认知绩效最近的证据表明,对注意力施加最大负荷的任务,
系统在作为行为生物标志物方面特别有用,
早期DAT,并与非痴呆老年人的其他生物标志物相关。拟议
研究计划将继续纵向跟踪一组健康的老年人和个人在早期
疾病过程的各个阶段,沿着有中风风险的个体,以更好地隔离
新的注意力控制措施的贡献,并调查在何种程度上,这些人
记忆力/注意力训练技术。我们将有三波测试,这将是
间隔约1.5年。每个参与者将在一个单一的会议测试的每一波
测试,持续约2小时。在每一波,我们将继续管理一个小电池(不
超过40分钟)的执行措施(计算跨度,Stroop,追溯性干扰
排除措施和短切换任务)。这将提供继续遵循这些
使用我们已有数据的同一组指标的个体。除了执行官
控制措施,我们还将使用实验程序,以提供三个不同的目标估计
每一波的成分。这些措施将包括:(a)通过
加工分离程序,(B)前瞻记忆表现的组成部分,和(c)标准
记忆操纵(即,重复测试、扩展检索、语义编码)。
我们将继续探索参与者可变性和反应成分的不同测量方法
导致观察到的变异性估计值发生任何变化的时间分布,作为
健康老龄化和早期DAT的认知变化。此外,由于最近的证据表明,某些
个性特征(例如,神经质和神经质)使个体易于发展DAT,我们
将探讨人格特征在认知标记中的调节作用,以及对
记忆技巧此外,我们最近发现,人格特征与
认知表现,包括变异性估计。最后,在项目3中获得的行为测定将
与来自可从其他项目和岩心获得的生物标志物的结果相关(例如,CSF,PIB,
遗传学和目标地区的体积测量),以确定哪些综合措施提供了
最好的行为生物标志物
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David A Balota其他文献
Development of a checklist for cognitive assessment requirements (CARE) based on a Delphi consensus study
- DOI:
10.1038/s41598-025-87380-2 - 发表时间:
2025-01-24 - 期刊:
- 影响因子:3.900
- 作者:
Vahid Nejati;Reza Estaji;Vicent Balanzá-Martínez;David A Balota;Suzanne Barker-Collo;Morris Bell;Jacquelyn H Berry;Khatereh Borhani;Munro Cullum;Anthony Feinstein;Charles J Golden;Raul Gonzalez;Jordan Henry Grafman;Steven D Hollon;Petra Jansen;Nicole A Kochan;Ryan Van Patten;Olivier Piguet;Sarah A Raskin;Sean B. Rourke;Andrew Scholey;Yaakov Stern;Steven Paul Woods;Michael I. Posner - 通讯作者:
Michael I. Posner
David A Balota的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David A Balota', 18)}}的其他基金
Behavioral an(j Neural Markers of Attentional Control: Antecedents for AD
注意力控制的行为和神经标记:AD 的前因
- 批准号:
8287323 - 财政年份:2011
- 资助金额:
$ 16.25万 - 项目类别:
ATTENTIONAL PROFILES AS AN EARLY MARKER FOR DAT
注意力概况作为 DAT 的早期标记
- 批准号:
6989341 - 财政年份:2005
- 资助金额:
$ 16.25万 - 项目类别:
Behavioral an(j Neural Markers of Attentional Control: Antecedents for AD
注意力控制的行为和神经标记:AD 的前因
- 批准号:
8522089 - 财政年份:2005
- 资助金额:
$ 16.25万 - 项目类别:
ATTENTION PROFILES IN HEALTHY AGING AND EARLY STAGE DAT
健康老龄化和早期 DAT 的注意力概况
- 批准号:
6697843 - 财政年份:2004
- 资助金额:
$ 16.25万 - 项目类别:
FRONTAL CONTROL /MEMORY IN AGING & SENILE DEMENTIA OF THE ALZHEIMER'S TYPE
前端控制/内存老化
- 批准号:
6563253 - 财政年份:2002
- 资助金额:
$ 16.25万 - 项目类别:
FRONTAL CONTROL /MEMORY IN AGING & SENILE DEMENTIA OF THE ALZHEIMER'S TYPE
前端控制/内存老化
- 批准号:
6299230 - 财政年份:2000
- 资助金额:
$ 16.25万 - 项目类别:
FRONTAL CONTROL /MEMORY IN AGING & SENILE DEMENTIA OF THE ALZHEIMER'S TYPE
前端控制/内存老化
- 批准号:
6097952 - 财政年份:1999
- 资助金额:
$ 16.25万 - 项目类别:
INHIBITORY CONTROL IN HEALTHY AGING AND SENILE DEMENTIA OF THE ALZHEIMER'S TYPE
健康老龄化和阿尔茨海默型老年痴呆症的抑制控制
- 批准号:
6267200 - 财政年份:1998
- 资助金额:
$ 16.25万 - 项目类别:
INHIBITORY CONTROL IN HEALTHY AGING AND SENILE DEMENTIA OF THE ALZHEIMER'S TYPE
健康老龄化和阿尔茨海默型老年痴呆症的抑制控制
- 批准号:
6233963 - 财政年份:1997
- 资助金额:
$ 16.25万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 16.25万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 16.25万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 16.25万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 16.25万 - 项目类别: